Drug Target Review – Issue 2 2020
Posted: 26 May 2020 | Drug Target Review | 1 comment
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
This issue includes:
High-throughput screening as a method for discovering new drugs
Matthew Lloyd, University of Bath
Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy
Shalom Gurjar, OXGENE
Neoantigens: presenting new vaccine opportunities in immuno-oncology
Nikki Withers, Drug Target Review
Data, data and still more data: the challenges of imaging and analysing 3D cell models
Margaritha Mysior, University College Dublin
Jeremy Simpson, University College Dublin
- STEM CELLS
Application of organoid technology for retinal disease modelling and drug discovery
Valeria Chichagova, Newcastle University and Newcells Biotech
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Antibodies, Drug Development, Drug Discovery, Drug Targets, Genomics, High-Throughput Screening (HTS), Imaging, Immuno-oncology therapeutics, Research & Development, Stem Cells
Very informative article..